Nucleoside analogues in the treatment of haematological malignancies

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 6, 2001, Pages 929-943

  Johnson, S A ^a  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

Author keywords

Cladribine; Clofarabine; Cytarabine; Fludarabine; Gemcitabine; Haematological malignancy; Nelarabine; Nucleosides; Troxacitabine

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE; ANTIMETABOLITE; BUSULFAN; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTARABINE 5' STEARYLPHOSPHATE; CYTOTOXIC AGENT; DEOXYRIBONUCLEOTIDE; DEXAMETHASONE; DNA; DOXORUBICIN; FLUDARABINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; LIPOSOME; MELPHALAN; MITOXANTRONE; NELARABINE; NUCLEOSIDE ANALOG; PENTOSTATIN; RETINOIC ACID; THYMOCYTE ANTIBODY; TROXACITABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; BLOOD TOXICITY; CANCER GRADING; CELL DIVISION; CHRONIC LYMPHATIC LEUKEMIA; DRUG ACTIVITY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; ENCAPSULATION; HAIRY CELL LEUKEMIA; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; NAUSEA; NONHODGKIN LYMPHOMA; OUTPATIENT CARE; REVIEW; SOLID TUMOR; STEM CELL TRANSPLANTATION; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOSIDES; BIOLOGICAL TRANSPORT; CLADRIBINE; CLINICAL TRIALS; CYTARABINE; CYTOSINE; DEOXYCYTIDINE; DIOXOLANES; ECONOMICS, PHARMACEUTICAL; GUIDELINES; HEMATOLOGIC NEOPLASMS; HUMANS; MOLECULAR STRUCTURE; NUCLEOSIDES; PENTOSTATIN; VIDARABINE;

EID: 0034872409     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.6.929     Document Type: Review

References (153)

1. Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults
2. Modulation of 9-β-D-arabinofuranosyladenine 5′-triphosphate and deoxyadenosine triphosphate in leukaemic cells by 2′deoxycoformycin during therapy with 9-β-D arabinofuranosyladenine
3. Effectiveness of Pentostatin (2′deoxycoformycin) in refractory lymphoid neoplasms
4. Phase I clinical investigation of 9-β-arabinosyl-2-fluoroadenine 5′-monophosphate (NSC 312887) a new purine antimetabolite
5. Specific toxicity of 2-chlorodeoxyadenosine towards resting and proliferating human lymphocytes
6. 2-chloro-2′-fluroarabinosyladenine: Pharmacokinetics and action in chronic lymphocytic leukemia cells
7. Evaluation of the antitumour activity of gemcitabine (2′2′-difluoro-2′-deoxycytidine)
8. Potent antitumour activity of a novel nucleoside analogue BCH-4556 (β-L-dioxolane-cytidine) in human renal cell carcinoma xenograft models
9. 2-amino-6-methoxypurine arabinoside: An agent for T-cell malignancies
10. Functional compartmentation of dCTP pools: Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts
11. Clinical pharmacokinetics of nucleoside analogues: Focus on haematological malignancies
12. Remission induction with adenosine deaminase inhibitor 2′deoxycoformycin in thylymphoblastic leukaemia
13. Phase I-II clinical and pharmacodynamic study of effects of 2′deoxycoformycin administered by continuous infusion in children with refractory acute lymphoblastic leukemia
14. Definition of safe, effective dosing regimen of 2′-deoxycoformycin with biochemical investigation
15. Hairy Cell Leukemia: Induction of complete remission with pentostatin (2′deoxycoformycin)
16. Long term follow-up of remission duration, mortality and second malignancies in hairy cell leukemia patients treated with pentostatin
17. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha resistant hairy cell leukemia
18. Clinical pharmacology of deoxycoformycin
19. Clinical pharmacokinetics of 2′deoxycoformycin in renal impairment
20. Deoxycoformycin: Neurological toxicity
21. An investigation of 2′deoxycoformycin in the treatment of cutaneous T-cell lymphoma
22. Phase I study of YK-176 (2′deoxycoformycin) in patients with Adult T-Cell Leukemia-Lymphoma
23. Phase I/II evaluation of pentostatin (2′deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia
24. A Phase I study of seven day continuous infusion deoxycoformycin
25. Kinetics of recovery of CD4+ T-cells in peripheral blood of deoxycoformycin-treated patients
26. Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity
27. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study
28. Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma
29. Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukaemia
30. Fludarabine therapy in chronic lymphocytic leukemia (CLL)
31. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage lymphocytic leukaemia
32. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
33. Pharmacokinetics of 2-F-araA (9-β-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the Phase I clinical investigation of Fludarabine phosphate
34. Pharmacokinetic study of fludarabine phosphate (NSC 312887)
35. Phase II trial of 9-β-D-arabinosyl-2-fluoroadenine 5′-monophosphate in non-Hodgkin's lymphoma: Prospective comparison of response with deoxycytidine kinase activity
36. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia
37. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia
38. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule
39. Fludarabine phosphate: A synthetic purine antimetabolite with significant activity against lymphoid malignancies
40. Phase II study of fludarabine phosphate in multiple myeloma
41. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte
42. Severe immunodeficiency in patients treated with fludarabine monophosphate
43. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia
44. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment
45. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies
46. Oral bioavailability of plasma fludarabine and fludarabine triphosphate (F-araA) in peripheral CLL cells
47. A pharmacokinetic study of single doses of oral fludarabine phosphate
48. Comparison of the pharmacokinetics and bioavailability of oral fludarabine administered either fasting or after food
49. Modulation of arabinosyl nucleoside metabolism by arabinosyl nucleotides in human leukemia cells
50. Use of granulocyte colony-stimulating factor before, during, and after fludarabine cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with without granulocyte colony-stimulating factor
51. Randomised Phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
52. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy
53. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia
54. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair
55. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: A Phase II study
56. Sequential cis-platinum, fludarabine and arabinosyl cytosine (PFA) or cyclophosphamide, fludarabine and arabinosyl cytosine (CFA) in patients with Richter's Syndrome: A pilot study
57. Fludarabine, cisplatin, and araC in patients with anthracycline-refractory intermediate-grade and high-grade non-Hodgkin's lymphoma: The International Oncology Study Group (IOSG) NHL 2 study
58. FluDAP: Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma
59. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia
60. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia
61. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma
62. Fludarabine, mitoxantrone and dexamethasone: An effective new regimen for indolent lymphoma
63. Fludarabine and mitoxantrone: A highly effective and well-tolerated salvage therapy for low-grade lymphoproliferative disorders
64. Randomized trial of fludarabine versus fludarabine and idarubicin as front-line treatment in patients with indolent or mantle cell lymphoma
65. Fludarabine and cyclophosphamide: Synergistic cytotoxicity associated with inhibition of interstrand cross-link removal
66. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia
67. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest Oncology Group Study
68. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: Results and long-term follow-up - A report from the Eastern Cooperative Oncology Group
69. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent malignancies
70. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
71. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders
72. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
73. Non myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases
74. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
75. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft versus malignancy
76. Fludarabine-based non-myeloablative chemotherapy followed by infusions of HLA-identical stem cells for relapsed leukaemia and lymphoma
77. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies
78. Fludarabine-containing regimes severely impair peripheral blood stem cell mobilization and collection in acute myeloid leukaemia patients
79. Fludarabine-containing regimens may adversely affect peripheral blood stem-cell collection in low-grade non-Hodgkin's lymphoma patients
80. Antileukemic and immunosuppressive activity of 2-chlorodeoxyadenosine
81. 2-Chlorodeoxyadenosine (2-CdA): A potent chemotherapeutic and immunosuppressive nucleoside
82. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy
83. On the bioavailability of oral and subcutaneous 2-chloro-2-deoxyadenosine in humans: Alternative routes of administration
84. Determination of 2-chloro-2′-deoxyadenosine in human plasma
85. Cladribine (2-chlorodeoxyadenosine)
86. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine
87. 2-Chlorodeoxyadenosine dose-escalation in non-hematological malignancies
88. A Phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumours
89. A Phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia
90. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukaemia
91. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia
92. Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients
93. A Phase I study of intermittent infusion cladribine in patients with solid tumors
94. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies
95. 2-chlorodeoxyadenosine an active agent in the treatment of cutaneous T-cell lymphoma
96. Two-hours iv infusion of 2-chlorodeoxyadenosine (2-CDA) in hairy cell leukaemia (HCL) is effective and may produce less CD4/CD8 ratio impairment. Results for the HOVON-23 study
97. 2-chlorodeoxyadenosine (CDA) by subcutaneous bolus injection: A Phase II study in Hairy Cell Leukemia (HCL)
98. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic Hairy Cell Leukaemia
99. 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia
100. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia
101. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia
102. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pre-treated chronic lymphocytic leukemia
103. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with Hairy Cell Leukemia
104. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma
105. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukaemia and lymphoma
106. Preclinical antitumor activity of 2-chloro-9(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine (Cl-F-ara-A)
107. Phase I clinical and pharmacological study of clofarabine
108. Comparison of three remission induction regimes and two post induction strategies for the treatment of acute non-lymphocytic leukemia: A Cancer and Leukemia Group B study
109. A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of cancer and leukaemia group B
110. A pilot study of high-dose 1-β-D-arabinofuranosyl cytosine for acute leukemia and refractory lymphoma: Clinical response and pharmacology
111. The cytosine arabinoside syndrome
112. Cerebellar toxicity with high-dose cytosine arabinoside
113. Clinical pharmacology of 1-β-D-arabinofuranosylcytosine
114. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis
115. Clinical pharmacology of encapsulated sustained-release cytarabine
116. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma - Phase I/II studies and pharmacokinetics
117. Efficacy of single-agent gemcitabine in advanced Non-Small Cell Lung Cancer: A review
118. An Investigational New Drug treatment program for patients with gemcitabine. Results for over 3000 patients with pancreatic carcinoma
119. Advanced breast cancer: A Phase II trial with gemcitabine
120. Phase II study of gemcitabine (2′,2′difluorodeoxycytidine) in previously treated ovarian cancer patients
121. A Phase II study of gemcitabine (LY188011) in patients with advanced squamous cell carcinoma of the head and neck
122. Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma
123. Gemcitabine: Current status of Phase I and II trials
124. A Phase I clinical, plasma and cellular pharmacology study of Gemcitabine
125. Weekly Gemcitabine in advanced or metastatic tumours. A clinical Phase I study
126. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre extended Phase II study
127. Gemcitabine in Leukemia: A Phase I clinical, plasma and cellular pharmacological study
128. Clinical results of a pharmacodynamically based strategy for higher dosing of gemcitabine in patients with solid tumours
129. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients
130. Gemcitabine for relapsed or resistant lymphoma
131. Preclinical combination therapy with gemcitabine and mechanisms of resistance
132. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer: Usefulness of mathematic modelling to determine maximum tolerated dose
133. Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small cell lung cancer
134. Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: A hoosier oncology group study
135. Phase I-II study of gemcitabine and weekly cisplatin in the treatment of advanced non-small cell lung cancer - Preliminary results
136. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer
137. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer
138. Combined cisplatin and gemcitabine for non-small cell lung cancer: Influence of scheduling on toxicity and drug delivery
139. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors
140. Gemcitabine-cisplatin: A schedule finding study
141. Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor
142. A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies
143. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer
144. Gemcitabine and paclitaxel: Pharmacokinetic and pharmacodynamic interaction in patients with non-small cell lung cancer
145. Chemo-radiotherapy: Radiosensitizing nucleoside analogues
146. Gemcitabine mediated radiosensitization
147. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia
148. Pharmacologic purging of malignant T cells from human bone marrow using 9-β-D-arabinosylguanine
149. 2 amino-9-β-D-arabinosyl-l-6-methoxy 9H guanine (GW506U) compound 506U) is highly active in patients with T-cell malignancies: Results of a Phase I trial in pediatric and adult patients with refractory hematological malignancies
150. Pharmacokinetics of nelarabine and 9-β-D-arabinofuranosylguanine in pediatric and adult patients during a Phase I study of nelarabine for the treatment of refractory hematologic malignancies
151. Pharmacoeconomic considerations of treating patients with acute leukaemia
152. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the UK
153. Pentostatin and cladribine for hairy cell leukaemia